Multiple biomarker strategy based on parathyroid hormone and natriuretic peptides testing for improved prognosis of chronic heart failure

Peptides

Volumn 64, Issue , 2015, Pages 24-28

  Gruson, Damien ^a,b   Ahn, Sylvie A ^b   Rousseau, Michel F ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Aldosterone; BNP; Heart failure; NT proBNP; Prognosis; PTH

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PARATHYROID HORMONE; BIOLOGICAL MARKER; NATRIURETIC FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DIURETIC THERAPY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; BLOOD; CHRONIC DISEASE; MIDDLE AGED; RISK; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; PARATHYROID HORMONE; PROGNOSIS; RISK; YOUNG ADULT;

EID: 84921047812     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2014.12.010     Document Type: Article

References (39)

1. H. Altay, and Y. Colkesen Parathyroid hormone and heart failure: novel biomarker strategy Endocr Metab Immune Disord Drug Targets 13 1 2013 100 104
2. H. Altay, A. Zorlu, S. Binici, M. Bilgi, M.B. Yilmaz, and Y. Colkesen Relation of serum parathyroid hormone level to severity of heart failure Am J Cardiol 109 January (2) 2012 252 256
3. J. Bernheim, and S. Benchetrit The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases Nephrol Dial Transpl 26 8 2011 2433 2438
4. E. Braunwald, and M.R. Bristow Congestive heart failure: fifty years of progress Circulation 102 November (20 Suppl. 4) 2000 IV14 IV23
5. L.D. Carbone, J.D. Cross, S.H. Raza, A.J. Bush, R.J. Sepanski, and S. Dhawan Fracture risk in men with congestive heart failure risk reduction with spironolactone J Am Coll Cardiol 52 July (2) 2008 135 138
6. E. Cavalier, P. Delanaye, P. Lukas, A. Carlisi, R. Gadisseur, and J.C. Souberbielle Standardization of DiaSorin and Roche automated third generation PTH assays with an International Standard: impact on clinical populations Clin Chem Lab Med 52 August (8) 2014 1137 1141
7. V.S. Chhokar, Y. Sun, S.K. Bhattacharya, R.A. Ahokas, L.K. Myers, and Z. Xing Hyperparathyroidism and the calcium paradox of aldosteronism Circulation 111 February (7) 2005 871 878
8. M. Curione, S. Amato, B.S. Di, L. Petramala, D. Cotesta, and C. Letizia Parathyroidectomy erase increased myocardial electrical vulnerability in patients with primary hyperparathyroidism Int J Cardiol 141 May (2) 2010 201 202
9. D. Devroey, and C.V. Van The incidence and first-year mortality of heart failure in Belgium: a 2-year nationwide prospective registration Int J Clin Pract 64 February (3) 2010 330 335
10. D. Gruson, T. Lepoutre, S.A. Ahn, J.M. Ketelslegers, and M.F. Rousseau Increased circulating concentrations of bioactive PTH 1-84 in patients with heart failure J Endocrinol Invest 35 December (11) 2012 987 991
11. D. Gruson, T. Lepoutre, S.A. Ahn, J.M. Ketelslegers, and M.F. Rousseau Comparison between intact and bioactive parathyroid hormone assays in patients with severe heart failure Clin Biochem 46 March (4-5) 2013 391 394
12. D. Gruson, T. Lepoutre, J.M. Ketelslegers, J. Cumps, S.A. Ahn, and M.F. Rousseau C-terminal FGF23 is a strong predictor of survival in systolic heart failure Peptides 37 October (2) 2012 258 262
13. O.M. Gutierrez, J.L. Januzzi, T. Isakova, K. Laliberte, K. Smith, and G. Collerone Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease Circulation 119 May (19) 2009 2545 2552
14. A. Halapas, R. Tenta, C. Pantos, D.V. Cokkinos, and M. Koutsilieris Parathyroid hormone-related peptide and cardiovascular system In Vivo 17 September (5) 2003 425 432
15. E. Kamycheva, J. Sundsfjord, and R. Jorde Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study Eur J Cardiovasc Prev Rehabil 11 February (1) 2004 69 74
16. R.N. Khouzam, D.A. Dishmon, V. Farah, S.D. Flax, L.D. Carbone, and K.T. Weber Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure Am J Med Sci 331 January (1) 2006 30 34
17. P.H. Law, Y. Sun, S.K. Bhattacharya, V.S. Chhokar, and K.T. Weber Diuretics and bone loss in rats with aldosteronism J Am Coll Cardiol 46 July (1) 2005 142 146
18. G. Li, S. Oparil, S.S. Kelpke, Y.F. Chen, and J.A. Thompson Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro Circulation 106 August (7) 2002 854 859
19. S. Liu, R. Guo, L.G. Simpson, Z.S. Xiao, C.E. Burnham, and L.D. Quarles Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX J Biol Chem 278 September (39) 2003 37419 37426
20. M.L. Melamed, J.A. Eustace, L.C. Plantinga, B.G. Jaar, N.E. Fink, and R.S. Parekh Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study Nephrol Dial Transpl 23 May (5) 2008 1650 1658
21. K.R. Neves, F.G. Graciolli, L.M. dos Reis, C.A. Pasqualucci, R.M. Moyses, and V. Jorgetti Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure Kidney Int 66 December (6) 2004 2237 2244
22. K. Ogino, K. Ogura, Y. Kinugasa, Y. Furuse, K. Uchida, and M. Shimoyama Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure J Clin Endocrinol Metab 87 October (10) 2002 4722 4727
23. B.D. Parker, L.J. Schurgers, V.M. Brandenburg, R.H. Christenson, C. Vermeer, and M. Ketteler The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study Ann Intern Med 152 May (10) 2010 640 648
24. M.R. Rutledge, V. Farah, A.A. Adeboye, M.R. Seawell, S.K. Bhattacharya, and K.T. Weber Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism Cardiovasc Drugs Ther 27 April (2) 2013 161 170
25. F.N. Saleh, H. Schirmer, J. Sundsfjord, and R. Jorde Parathyroid hormone and left ventricular hypertrophy Eur Heart J 24 November (22) 2003 2054 2060
26. L.L. Schierbeck, T.S. Jensen, U. Bang, G. Jensen, L. Kober, and J.E. Jensen Parathyroid hormone and vitamin D - markers for cardiovascular and all cause mortality in heart failure Eur J Heart Fail 13 June (6) 2011 626 632
27. K.D. Schluter, and H.M. Piper Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide Cardiovasc Res 37 January (1) 1998 34 41
28. Y. Selektor, R.A. Ahokas, S.K. Bhattacharya, Y. Sun, I.C. Gerling, and K.T. Weber Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism Am J Med Sci 335 February (2) 2008 105 110
29. J. Silver, M. Rodriguez, and E. Slatopolsky FGF23 and PTH - double agents at the heart of CKD Nephrol Dial Transplant 27 May (5) 2012 1715 1720
30. J.C. Souberbielle, H. Roth, and D.P. Fouque Parathyroid hormone measurement in CKD Kidney Int 77 January (2) 2010 93 100
31. T. Sugimoto, T. Tanigawa, K. Onishi, N. Fujimoto, A. Matsuda, and S. Nakamori Serum intact parathyroid hormone levels predict hospitalisation for heart failure Heart 95 March (5) 2009 395 398
32. K. Thygesen, J. Mair, C. Mueller, K. Huber, M. Weber, and M. Plebani Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care Eur Heart J 33 August (16) 2012 2001 2006
33. J. Tian, M. Smogorzewski, L. Kedes, and S.G. Massry Parathyroid hormone-parathyroid hormone related protein receptor messenger RNA is present in many tissues besides the kidney Am J Nephrol 13 3 1993 210 213
34. A. Tomaschitz, E. Ritz, B. Pieske, A. Fahrleitner-Pammer, K. Kienreich, and J.H. Horina Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease Cardiovasc Res 94 April (1) 2012 10 19
35. A. Tomaschitz, E. Ritz, B. Pieske, J. Rus-Machan, K. Kienreich, and N. Verheyen Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease Metabolism 62 1 2014 20 31
36. A. Vidal, Y. Sun, S.K. Bhattacharya, R.A. Ahokas, I.C. Gerling, and K.T. Weber Calcium paradox of aldosteronism and the role of the parathyroid glands Am J Physiol Heart Circ Physiol 290 January (1) 2006 H286 H294
37. K.C. Wollert Tailored therapy for heart failure: the role of biomarkers Eur Heart J 33 September (18) 2012 2246 2248
38. C. Wu, T.S. Kato, K. Pronschinske, S. Qiu, Y. Naka, and H. Takayama Dynamics of bone turnover markers in patients with heart failure and following haemodynamic improvement through ventricular assist device implantation Eur J Heart Fail 14 Dec (12) 2012 1356 1365
39. C.W. Yancy, M. Jessup, B. Bozkurt, F.A. Masoudi, J. Butler, and P.E. McBride ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 15 Oct (16) 2013 e147 e239